Companies uniQure NV
uniQure (QURE): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me uniQure NV’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers36th pct.Of 12 peer CEOs
CEO pay, last three years
- $6,584,919FY2023
- $3,075,938FY2024
- $3,287,434FY2025
CEO total pay was $3,287,434 in fiscal 2025, up from $3,075,938 in fiscal 2024.
FY2025: salary $676,170 · bonus $0 · stock awards $1,079,100 · option awards $1,155,960
Executives and directors
Christian Klemt · CFOMatthew Kapusta · CEOWalid Abi-Saab · Chief Medical OfficerJeannette Potts · General CounselDavid Meek · Chair of the BoardJack Kaye · Independent DirectorJeremy Springhorn · Independent DirectorLeonard Post · Independent DirectorMadhavan Balachandran · Independent DirectorRachelle Jacques · Independent DirectorRobert Gut · Independent Director
Frequently asked questions
Who was the highest-paid executive at uniQure NV in fiscal 2025?
As disclosed, Matthew Kapusta (Chief Executive Officer and Executive Director) was the highest-paid executive at uniQure NV in fiscal 2025, with total compensation of $3,287,434.
How does uniQure NV's chief executive pay compare to its disclosed peer group?
As disclosed, Matthew Kapusta's total compensation ranked at the 36th percentile of uniQure NV's disclosed peer group.
What is uniQure NV's CEO-to-median employee pay ratio?
As disclosed, uniQure NV's CEO-to-median employee pay ratio was 19:1.
How did shareholders vote on uniQure NV's executive compensation?
As disclosed, 98.91% of shareholders supported uniQure NV's executive compensation in the latest say-on-pay vote.
How much does uniQure NV spend in total on board compensation for fiscal 2025?
As disclosed, uniQure NV reported total board compensation of $1,400,116 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Matthew Kapusta | $676,170 | $0 | $1,079,100 | $1,155,960 | $345,117 | $0 | $31,087 | $3,287,434 |
| Chief Executive Officer and Executive Director | ||||||||
| Christian Klemt | 539,220 | 0 | 795,700 | 851,760 | 197,755 | 0 | 22,975 | 2,407,410 |
| Chief Financial Officer | ||||||||
| Walid Abi-Saab | 583,798 | 0 | 414,200 | 446,160 | 258,250 | 0 | 103,230 | 1,805,638 |
| Chief Medical Officer | ||||||||
| Jeannette Potts | 495,012 | 0 | 381,500 | 405,600 | 178,344 | 0 | 39,471 | 1,499,927 |
| Chief Legal and Compliance Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Matthew Kapusta | $3,287,434 | $3,075,938 | $6,584,919 | ↑ +211,496 |
| Christian Klemt | 2,407,410 | 1,327,533 | 2,116,548 | ↑ +1,079,877 |
| Walid Abi-Saab | 1,805,638 | 1,499,857 | — | ↑ +305,781 |
| Jeannette Potts | 1,499,927 | 1,292,272 | 2,310,848 | ↑ +207,655 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
our compensation program for all of our executive officers, including our NEOs, is designed to attract, retain, and incentivize the best possible talent
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | WTW (Willis Towers Watson) |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Walid Abi-Saab | RSU | 2025-03-03 | — | — | 38,000 | — | $414,200 |
| Matthew Kapusta | RSU | 2025-03-03 | — | — | 99,000 | — | 1,079,100 |
| Walid Abi-Saab | OPTION | 2025-03-03 | — | — | 66,000 | — | 446,160 |
| Christian Klemt | OPTION | 2025-03-03 | — | — | 126,000 | — | 851,760 |
| Christian Klemt | RSU | 2025-03-03 | — | — | 73,000 | — | 795,700 |
| Jeannette Potts | OPTION | 2025-03-03 | — | — | 60,000 | — | 405,600 |
| Jeannette Potts | RSU | 2025-03-03 | — | — | 35,000 | — | 381,500 |
| Matthew Kapusta | OPTION | 2025-03-03 | — | — | 171,000 | — | 1,155,960 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Walid Abi-Saab | $414,200 | $0 | $446,160 | 0.0% |
| Matthew Kapusta | 1,079,100 | 0 | 1,155,960 | 0.0% |
| Christian Klemt | 795,700 | 0 | 851,760 | 0.0% |
| Jeannette Potts | 381,500 | 0 | 405,600 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Christian Klemt | Option | 4,707 | 16.04 | — |
| Christian Klemt | RSU | 12,468 | — | 298,359 |
| Matthew Kapusta | Option | 13,486 | 16.04 | — |
| Jeannette Potts | RSU | 15,702 | — | 375,749 |
| Christian Klemt | Option | 20,158 | 20.06 | — |
| Walid Abi-Saab | RSU | 22,402 | — | 536,080 |
| Walid Abi-Saab | PSU | 25,000 | — | 2,393,000 |
| Christian Klemt | RSU | 33,001 | — | 789,714 |
| Walid Abi-Saab | RSU | 33,001 | — | 789,714 |
| Jeannette Potts | RSU | 33,001 | — | 789,714 |
| Jeannette Potts | RSU | 35,000 | — | 837,550 |
| Walid Abi-Saab | RSU | 38,000 | — | 909,340 |
| Matthew Kapusta | RSU | 40,502 | — | 969,213 |
| Walid Abi-Saab | Option | 43,428 | 11.47 | — |
| Christian Klemt | Option | 48,096 | 5.59 | — |
| Walid Abi-Saab | Option | 48,096 | 5.59 | — |
| Jeannette Potts | Option | 48,096 | 5.59 | — |
| Jeannette Potts | Option | 60,000 | 10.9 | — |
| Christian Klemt | RSU | 73,000 | — | 1,746,890 |
| Matthew Kapusta | Option | 80,158 | 20.06 | — |
| Matthew Kapusta | RSU | 99,000 | — | 2,369,070 |
| Jeannette Potts | RSU | 99,080 | — | 2,370,985 |
| Matthew Kapusta | RSU | 100,001 | — | 2,393,024 |
| Christian Klemt | RSU | 107,476 | — | 2,571,901 |
| Christian Klemt | Option | 126,000 | 10.9 | — |
| Walid Abi-Saab | RSU | 145,951 | — | 3,492,608 |
| Matthew Kapusta | Option | 145,971 | 5.59 | — |
| Matthew Kapusta | Option | 171,000 | 10.9 | — |
| Matthew Kapusta | RSU | 203,010 | — | 4,858,029 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| David MeekIndependent · Board Chair · Compensation · Nominating/Governance · Commercial | $97,541 | $129,273 | $137,857 | — | $0 | $364,671 |
| Jeremy SpringhornIndependent · Audit · Nominating/Governance (Chair) · Research & Development · Commercial | 77,541 | 129,273 | 137,857 | — | 0 | 344,671 |
| Jack KayeIndependent · Audit (Chair) · Compensation | 72,500 | 129,273 | 137,857 | — | 0 | 339,630 |
| Rachelle JacquesIndependent · Audit · Nominating/Governance · Commercial (Chair) | 70,082 | 129,273 | 137,857 | — | 0 | 337,212 |
| Madhavan BalachandranIndependent · Compensation (Chair) · Commercial | 65,041 | 129,273 | 137,857 | — | 0 | 332,171 |
| Leonard PostIndependent · Research & Development (Chair) | 60,000 | 129,273 | 137,857 | — | 0 | 327,130 |
| Robert GutIndependent · Research & Development | 52,500 | 129,273 | 137,857 | — | 0 | 319,630 |
| Matthew KapustaEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | All Executive Officers have satisfied, or are on track to satisfy within the five-year grace period, the Board's stock ownership guidelines. |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $495,205 |
| Equity awards (grant-date value) | $904,911 |
| All other compensation | $0 |
| Total cost of the board | $1,400,116 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names uniQure as a peer
Companies that benchmark against QURE
3 companies name QURE as a compensation peer
- ADC Therapeutics SAADCTFY2025
- Akebia Therapeutics, Inc.AKBAFY2025
- ROCKET PHARMACEUTICALS, INC.RCKTFY2024
Each company listed discloses QURE in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named QURE in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
SLDB Solid BiosciencesALEC Alector, Inc.WVE Wave Life SciencesVYGR Voyager TherapeuticsCCCC C4 TherapeuticsFHTX Foghorn TherapeuticsTVTX Travere TherapeuticsCOGT Cogent BiosciencesSTOK Stoke TherapeuticsSGMO Sangamo TherapeuticsVERV Verve TherapeuticsRVNC Revance Therapeutics
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Cogent Biosciences | 2025 | Andrew Robbins | $724,554 | $12,993,250 | $13,447,680 | $561,600 | $27,762,684 |
| 2 | Stoke Therapeutics | 2025 | Ian Smith | 170,625 | 11,590,000 | 14,035,067 | 0 | 27,031,655 |
| 3 | Wave Life Sciences | 2025 | Paul Bolno | 700,000 | 1,420,540 | 9,506,300 | 614,250 | 12,277,916 |
| 4 | Revance Therapeutics | 2023 | Mark Foley | 720,000 | 8,810,731 | 0 | 522,720 | 10,068,915 |
| 5 | Travere Therapeutics | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 6 | Verve Therapeutics | 2024 | Sekar Kathiresan | 639,231 | 1,683,000 | 4,727,372 | 378,972 | 7,442,663 |
| 7 | Solid Biosciences | 2025 | Alexander Cumbo | 650,988 | 2,318,275 | 1,792,397 | 0 | 5,223,442 |
| 8 | uniQure NV | 2025 | Matthew Kapusta | 676,170 | 1,079,100 | 1,155,960 | 345,117 | 3,287,434 |
| 9 | C4 Therapeutics | 2025 | Andrew Hirsch | 694,925 | 710,730 | 848,007 | 573,313 | 2,940,975 |
| 10 | Voyager Therapeutics | 2025 | Alfred Sandrock | 674,903 | 611,900 | 843,900 | 361,917 | 2,508,370 |
| 11 | Foghorn Therapeutics | 2025 | Adrian Gottschalk | 638,000 | 0 | 1,334,037 | 385,990 | 2,361,027 |
| 12 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| — | Sangamo Therapeutics | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| uniQure NV | not disclosed | Options 50 · RSU 50 | No | WTW (Willis Towers Watson) |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| C4 Therapeutics | 120% | not disclosed | not disclosed | Pearl Meyer |
| Cogent Biosciences | 135% | not disclosed | No | Compensia |
| Foghorn Therapeutics | not disclosed | Options 100 | not disclosed | Pay Governance, LLC |
| Revance Therapeutics | 96.8% | PSU 100 | No | FW Cook |
| Sangamo Therapeutics | not disclosed | not disclosed | not disclosed | Aon |
| Solid Biosciences | 100% | not disclosed | No | Radford (AON Hewitt) |
| Stoke Therapeutics | not disclosed | not disclosed | not disclosed | Aon |
| Travere Therapeutics | 150% | not disclosed | No | Aon |
| Verve Therapeutics | not disclosed | not disclosed | not disclosed | Radford Data & Analytics from Aon plc |
| Voyager Therapeutics | 97.5% | not disclosed | No | Alpine Rewards, LLC |
| Wave Life Sciences | 135% | not disclosed | not disclosed | Aon Consulting Inc. |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 37,422,626 | 414,084 | 72,709 | 98.91% | Passed |
| 2025 | 2025-06-11 | 32,363,219 | 1,599,559 | 119,528 | 95.29% | Passed |
| 2024 | 2024-06-18 | 20,150,415 | 5,870,009 | 40,148 | 77.44% | Passed |
| 2022 | 2022-06-14 | 30,883,737 | 939,642 | 13,034 | 97.05% | Passed |
| 2019 | 2019-06-19 | 27,100,012 | 17,640 | 3,361 | 99.92% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-10 | 98.91%a |
| 2025 | 2025-06-11 | 95.29%b |
| 2024 | 2024-06-18 | 77.44%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of this vote.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 19 : 1 |
|---|---|
| CEO total compensation | $3,287,434 |
| Median employee compensation | $170,377 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Walid Abi-Saab | Chief Medical Officer | 2026-05-08 | D | 25,000 | $25 | $627,500 | Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-05-08 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-05-08 | D | 20,000 | 25 | 500,000 | Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-05-08 | A | 25,000 | 6 | 139,750 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-03 | D | 2,645 | 30 | 79,376 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-03 | A | 2,645 | 16 | 42,426 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-03 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-10 | A | 13,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-10 | A | 7,550 | 0 | 0 | Common | Form 4 ↗ |
| Robert Gut | Director | 2026-06-10 | D | 1,780 | 26 | 46,369 | Common | Form 4 ↗ |
| Robert Gut | Director | 2026-06-10 | D | 2,645 | 26 | 68,955 | Common | Form 4 ↗ |
| Robert Gut | Director | 2026-06-10 | A | 2,645 | 16 | 42,426 | Common | Form 4 ↗ |
| Robert Gut | Director | 2026-06-10 | D | 2,645 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Gut | Director | 2026-06-10 | D | 3,127 | 26 | 81,396 | Common | Form 4 ↗ |
| David Meek | Director | 2026-06-10 | A | 13,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-10 | A | 7,550 | 0 | 0 | Common | Form 4 ↗ |
| Rachelle Jacques | Director | 2026-06-10 | A | 13,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonard Post | Director | 2026-06-10 | A | 13,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leonard Post | Director | 2026-06-10 | A | 7,550 | 0 | 0 | Common | Form 4 ↗ |
| Jeremy Springhorn | Director | 2026-06-10 | A | 13,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Gut | Director | 2026-06-10 | A | 13,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-10 | A | 13,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rachelle Jacques | Director | 2026-06-10 | A | 7,550 | 0 | 0 | Common | Form 4 ↗ |
| Jeremy Springhorn | Director | 2026-06-10 | A | 7,550 | 0 | 0 | Common | Form 4 ↗ |
| Robert Gut | Director | 2026-06-10 | A | 7,550 | 0 | 0 | Common | Form 4 ↗ |
| David Meek | Director | 2026-06-10 | A | 7,550 | 0 | 0 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-11 | D | 1,993 | 27 | 53,931 | Common | Form 4 ↗ |
| Kylie O'Keefe | Chief Customer & Strat Officer | 2026-06-11 | D | 15,936 | 27 | 431,228 | Common | Form 4 ↗ |
| Rachelle Jacques | Director | 2026-06-11 | D | 1,993 | 27 | 53,931 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-11 | D | 1,993 | 27 | 53,931 | Common | Form 4 ↗ |
| Leonard Post | Director | 2026-06-11 | D | 1,993 | 27 | 53,931 | Common | Form 4 ↗ |
| Jeremy Springhorn | Director | 2026-06-11 | D | 1,993 | 27 | 53,931 | Common | Form 4 ↗ |
| Robert Gut | Director | 2026-06-11 | D | 2,726 | 27 | 73,766 | Common | Form 4 ↗ |
| David Meek | Director | 2026-06-11 | D | 1,993 | 27 | 53,931 | Common | Form 4 ↗ |
| Jeannette Potts | Chief Legal Officer | 2026-06-15 | D | 5,237 | 28 | 144,908 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-15 | A | 10,000 | 8 | 84,900 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-15 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-15 | D | 10,000 | 28 | 278,500 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-17 | D | 5,295 | 47 | 249,289 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-17 | D | 5,295 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-17 | A | 5,295 | 32 | 167,904 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-17 | D | 5,295 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-17 | A | 6,390 | 19 | 123,902 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 11,585 | 49 | 563,610 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 33,334 | 45 | 1,500,363 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 32,581 | 45 | 1,466,797 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 23,977 | 43 | 1,021,660 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-17 | D | 6,390 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-17 | D | 1,690 | 43 | 71,994 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-17 | D | 4,700 | 44 | 205,202 | Common | Form 4 ↗ |
| Madhavan Balachandran | Director | 2026-06-17 | A | 5,295 | 32 | 167,904 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 62,581 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 56,929 | 43 | 2,472,426 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | A | 62,581 | 19 | 1,213,446 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-17 | D | 5,295 | 43 | 225,408 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-17 | D | 6,023 | 44 | 263,205 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-18 | A | 4,656 | 32 | 147,642 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-18 | D | 4,656 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-18 | D | 37,015 | 50 | 1,850,750 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-18 | D | 4,656 | 50 | 232,800 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-24 | D | 4,128 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-24 | D | 6,696 | 50 | 334,800 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-24 | A | 4,128 | 32 | 130,899 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-25 | D | 28,716 | 50 | 1,436,374 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-25 | D | 28,716 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-06-25 | A | 28,716 | 32 | 910,584 | Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-06-26 | D | 1,434 | 47 | 67,197 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-30 | A | 17,060 | 20 | 344,271 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-30 | D | 4,107 | 46 | 190,934 | Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-06-30 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-06-30 | D | 10,000 | 46 | 464,600 | Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-06-30 | D | 20,000 | 46 | 928,000 | Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-06-30 | A | 10,000 | 6 | 55,900 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-30 | D | 17,060 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-30 | D | 4,107 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-30 | D | 17,060 | 46 | 792,096 | Common | Form 4 ↗ |
| Jack Kaye | Director | 2026-06-30 | A | 4,107 | 37 | 151,959 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-07-02 | D | 4,282 | 45 | 194,531 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-07-02 | D | 21,082 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-07-02 | D | 7,600 | 46 | 348,764 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-07-02 | A | 21,082 | 19 | 408,780 | Common | Form 4 ↗ |
| Matthew Kapusta | Director | 2026-07-02 | D | 9,200 | 44 | 408,756 | Common | Form 4 ↗ |
| Walid Abi-Saab | Chief Medical Officer | 2026-10-30 | A | 18,750 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (122 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Matthew Kapusta. DEF 14A, filed 2026-04-27. Section “SUMMARY COMPENSATION TABLE”. As printed: 3,287,434. View filing ↗
- Section 01, Christian Klemt. DEF 14A, filed 2026-04-27. Section “SUMMARY COMPENSATION TABLE”. As printed: 2,407,410. View filing ↗
- Section 01, Walid Abi-Saab. DEF 14A, filed 2026-04-27. Section “SUMMARY COMPENSATION TABLE”. As printed: 1,805,638. View filing ↗
- Section 01, Jeannette Potts. DEF 14A, filed 2026-04-27. Section “SUMMARY COMPENSATION TABLE”. As printed: 1,499,927. View filing ↗
- Section 03, Walid Abi-Saab RSU. DEF 14A, filed 2026-04-27. Section “GRANTS OF PLAN-BASED AWARDS FOR FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Matthew Kapusta RSU. DEF 14A, filed 2026-04-27. Section “GRANTS OF PLAN-BASED AWARDS FOR FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Walid Abi-Saab OPTION. DEF 14A, filed 2026-04-27. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Christian Klemt OPTION. DEF 14A, filed 2026-04-27. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Christian Klemt RSU. DEF 14A, filed 2026-04-27. Section “GRANTS OF PLAN-BASED AWARDS FOR FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Jeannette Potts OPTION. DEF 14A, filed 2026-04-27. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Jeannette Potts RSU. DEF 14A, filed 2026-04-27. Section “GRANTS OF PLAN-BASED AWARDS FOR FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Matthew Kapusta OPTION. DEF 14A, filed 2026-04-27. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-27. Section “CEO Pay Ratio”. As printed: 19 : 1. View filing ↗
- Section 08, David Meek. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 364,671. View filing ↗
- Section 08, Jeremy Springhorn. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 344,671. View filing ↗
- Section 08, Jack Kaye. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 339,630. View filing ↗
- Section 08, Rachelle Jacques. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 337,212. View filing ↗
- Section 08, Madhavan Balachandran. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 332,171. View filing ↗
- Section 08, Leonard Post. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 327,130. View filing ↗
- Section 08, Robert Gut. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 319,630. View filing ↗
- Section 08, Matthew Kapusta. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Walid Abi-Saab 2026-05-08. Form 4, filed 2026-05-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Walid Abi-Saab 2026-05-08. Form 4, filed 2026-05-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Walid Abi-Saab 2026-05-08. Form 4, filed 2026-05-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Walid Abi-Saab 2026-05-08. Form 4, filed 2026-05-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jack Kaye 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jack Kaye 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jack Kaye 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Madhavan Balachandran 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Madhavan Balachandran 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Gut 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Gut 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Gut 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Gut 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Gut 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Meek 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jack Kaye 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rachelle Jacques 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard Post 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard Post 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Springhorn 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Gut 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jack Kaye 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rachelle Jacques 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Springhorn 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Gut 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Meek 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Madhavan Balachandran 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kylie O'Keefe 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rachelle Jacques 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jack Kaye 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leonard Post 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Springhorn 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Gut 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Meek 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeannette Potts 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Madhavan Balachandran 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Madhavan Balachandran 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Madhavan Balachandran 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Madhavan Balachandran 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jack Kaye 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jack Kaye 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Madhavan Balachandran 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Madhavan Balachandran 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Madhavan Balachandran 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Madhavan Balachandran 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Madhavan Balachandran 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Madhavan Balachandran 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jack Kaye 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-18. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-25. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-25. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-06-25. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Walid Abi-Saab 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jack Kaye 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jack Kaye 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Walid Abi-Saab 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Walid Abi-Saab 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Walid Abi-Saab 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Walid Abi-Saab 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jack Kaye 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jack Kaye 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jack Kaye 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jack Kaye 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Kapusta 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Walid Abi-Saab 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-15. Item 5.07 · say-on-pay result. As reported: 98.91% (votes for as printed: 37,422,626). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-13. Item 5.07 · say-on-pay result. As reported: 95.29% (votes for as printed: 32,363,219). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-20. Item 5.07 · say-on-pay result. As reported: 77.44% (votes for as printed: 20,150,415). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 495,205 + equity 904,911 + all other 0 = 1,400,116, summed across the director compensation table rows.
- Cogent Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Cogent Biosciences's own proxy. As printed: 27,762,684. View filing ↗
- Stoke Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Stoke Therapeutics's own proxy. As printed: 27,031,655. View filing ↗
- Wave Life Sciences, Section 10b CEO total. DEF 14A, filed 2026-10-14. CEO total compensation as printed in Wave Life Sciences's own proxy. As printed: 12,277,916. View filing ↗
- Revance Therapeutics, Section 10b CEO total. DEF 14A, filed 2024-03-21. CEO total compensation as printed in Revance Therapeutics's own proxy. As printed: 10,068,915. View filing ↗
- Travere Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Travere Therapeutics's own proxy. As printed: 8,457,151. View filing ↗
- Verve Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-25. CEO total compensation as printed in Verve Therapeutics's own proxy. As printed: 7,442,663. View filing ↗
- Solid Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Solid Biosciences's own proxy. As printed: 5,223,442. View filing ↗
- uniQure NV (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in uniQure NV's own proxy. As printed: 3,287,434. View filing ↗
- C4 Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in C4 Therapeutics's own proxy. As printed: 2,940,975. View filing ↗
- Voyager Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Voyager Therapeutics's own proxy. As printed: 2,508,370. View filing ↗
- Foghorn Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Foghorn Therapeutics's own proxy. As printed: 2,361,027. View filing ↗
- Alector, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. View filing ↗